Results 191 to 200 of about 38,591 (254)
Abstract Since 1858, human atherosclerotic plaques have been shown to contain immune cells. But are these cells suitable therapeutic targets? Dozens of clinical trials of anti‐inflammatory agents other than colchicine have been performed in patients with clinically evident atherosclerosis.
Kevin Jon Williams
wiley +1 more source
ABSTRACT Artificial intelligence (AI) enables automated, high‐throughput adiposity quantification, offering refined risk stratification for women with overweight and obesity. We systematically reviewed and meta‐analyzed studies evaluating AI‐based segmentation of visceral, subcutaneous, and total fat in adult women populations (BMI: 25–29.9 and ≥ 30 kg/
Asefa Adimasu Taddese, Bjorn T. Tam
wiley +1 more source
ABSTRACT Introduction The paper aims to assess the effects of GLP‐1 RAs, structured exercise, and their combination on body composition and cardiometabolic outcomes in adults with overweight or obesity. Methods PubMed, Web of Science, Scopus, and EBSCO were searched through April 2026 for English‐language RCTs using terms related to obesity, GLP‐1 RAs,
Matteo Vandoni +6 more
wiley +1 more source
The Role of Lightning in Atmospheric Chemistry
Abstract Lightning has important effects on atmospheric constituents in primarily the middle and upper troposphere. We summarize the effects of lightning on atmospheric chemistry that have been published since the last major review in 2007. The estimates of NOx production by lightning (LNOx) are based on five methods: theoretical/laboratory estimates ...
Kenneth E. Pickering +2 more
wiley +1 more source
Bioscience students were asked for their opinions on the value and teaching of skills. 204 responded that teamwork, time management and study skills are necessary to reach University, that scientific writing, research, laboratory and presentation skills are taught effectively during their studies, while other skills are gained inherently through study ...
Janella Borrell, Susan Crennell
wiley +1 more source
Abstract INTRODUCTION ABvac40 is an active immunotherapy targeting Aβ40, the main component of cerebrovascular deposition in Alzheimer's disease (AD). A 24‐month randomized, placebo‐controlled phase 2 study (Part A) showed favorable safety and robust immunogenicity, with exploratory signals of clinical efficacy.
María Pascual‐Lucas +15 more
wiley +1 more source

